February 10, 2021, Singapore – Evive Biotech Ltd. (Evive Biotech), an innovative global biopharmaceutical company developing novel biological therapeutics, announced today that it has entered into a joint venture agreement with Dr. Xiao Qiang Yan to form ITabMed Co., Ltd (ITabMed Co.) to further advance the bispecific Immuno-Therapy Antibody (ITab) platform.

Dr. Xiao Qiang Yan previously served as Chairman and Chief Scientific Officer of Generon Corporation (now Evive Biotech).

“We are excited to be launching ITabMed Co. and to be continuing our relationship with Dr. Xiao Qiang Yan”, said Dr. Jubo Liu, Evive Biotech’s CEO. “This agreement will allow Evive and Dr. Xiao Qiang Yan to bring greater focus and resources to the ITab platform and help realize our shared goal of addressing unmet medical needs in immune oncology.”

Evive will continue to investigate and develop novel bi-specific antibodies through its broader, long-acting bi-specific platform, and will also have priority commercial rights to existing products that have been developed through ITabMed Co. Together with its other validated DiKine platform, a fusion protein platform focused on novel cytokine targets, Evive Biotech is well positioned to continue to build on its successful global trials and move to the next stage of its journey as it explores commercialization partners to bring its revolutionary remedies to patients worldwide.

“I am very pleased to have the opportunity to lead the further development of the ITab platform”, said Dr. Xiao Qiang Yan, CEO of ITabMed Co. “ITab has great potential to produce therapeutic bispecific antibodies. We are confident that this collaboration will deliver scientific developments, which will ultimately be beneficial to patients with limited treatment options.”

***ENDS***

Notes for editors

About Evive Biotech

Evive Biotech is a global biologics company with Asian roots, developing a portfolio of novel biological therapies for patients and healthcare professionals worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology and inflammatory disorders. Founded in 2004, we have over 200 employees today with operations in the US, Singapore and China. We adopt a holistic approach to drug development, combining exceptional research and commercialization capabilities with world class in-house regulatory expertise to bring innovative therapies to market quickly and efficiently. Our state-of-the art in-house cGMP facility allows us to manufacture at commercial scale in accordance with FDA, EMA and NMPA standards and industry best practices. Through partnerships with industry, physicians, and regulatory authorities, we develop revolutionary remedies that we believe will make a real and lasting difference to patients and their families worldwide. To learn more, visit www.evivebiotech.com.

About ITabMed Co.

ITabMed Co is a joint venture formed between Evive Biotech and Dr. Xiao Qiang Yan to further develop the ITab platform. ITab is a fully developed platform to produce therapeutic bispecific antibodies to address unmet medical needs in immune oncology. It provides significant flexibility to place domains that recognize two different epitopes or antigens of choice, with the affinity of choice, thus generating dual-targeting therapeutic assets on demand. Multiple ITab products are in preclinical and clinical stages of development. 

For further information, please contact:

Brunswick Group

evive.biotech@brunswickgroup.com

+65 6426 8188